News

Cocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study Costs

NASDAQ

(RTTNews) - Cocrystal Pharma, Inc. (COCP), a clinical stage biotechnology firm, on Sunday reported a wider loss in its third quarter, driven by higher clinical trial and related expenses mainly associated with the Phase 1b norovirus challenge study of norovirus candidate CDI-988.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.